Advent International completed €1.9bn acquisition of Zentiva, an international pharmaceutical company focused on developing, manufacturing and marketing modern generic pharmaceutical products, from Sanofi, a French multinational pharmaceutical company headquartered in Paris. “Zentiva is a robust business with a highly talented workforce and we believe it has demonstrated its potential for growth. Following a comprehensive review of strategic options for our generics unit in Europe, we have determined that transferring this business to Advent is the best option to ensure its long-term success,” said Olivier Brandicourt, Chief Executive Officer, Sanofi.